Quiets your appetite
Orforglipron mimics GLP-1, a natural fullness hormone your gut releases when you eat, reducing hunger, cravings and the background “food noise” between meals.
Available now · MHRA approved 10 August 2026
Foundayo, from £89.
A once-daily orforglipron tablet for weight loss, MHRA approved on 10 August 2026 and available at Curate now. Taken at any time of day, with or without food. No needles, no fasting window, no subscription.
Choose your daily dose
Price£8930-day supply · one-time purchase · no subscription
Start consultation · 4 minOrder today · dispatched once approved
A UK-registered clinician reviews your order before anything is dispensed; if it isn’t right for you a refund will be set up in line with our terms and conditions.
- GPhC pharmacy 9012920
- CQC-regulated prescribing
- No subscription
How it works
A GLP-1 that fits around your day.
Orforglipron is a small-molecule GLP-1 receptor agonist. Unlike the peptide-based tablets before it, it survives digestion on its own. That's what removes the fasting rules: any time of day, with or without food or water.
Slows digestion
Food leaves your stomach more gradually, so you feel genuinely satisfied with smaller portions. Less restriction, more off-switch.
Steadies blood sugar
The same pathway helps your body manage blood sugar levels, supporting steadier energy alongside the weight loss itself.
How ordering works
Reviewed properly, delivered quickly.
Three short steps, and the first one takes four minutes. You pay when you order, and your treatment ships as soon as a clinician approves it.
Start your consultation
A 4-minute online consultation about your health and goals. No GP referral, no waiting room. Then choose your dose and place your order.
A clinician reviews your order
A UK-registered clinician checks Foundayo is right for you before anything is dispensed. If it isn't, a refund will be set up in line with our terms and conditions.
Dispatched discreetly
Once your order is approved, your treatment is dispatched in discreet, plain packaging by tracked delivery.
- average weight loss over 72 weeks at the highest dose*
- 11.2%
- lost 10% or more of their body weight in the same trial
- 54.6%
- average reduction in waist circumference over 72 weeks*
- 10.1cm
- one daily tablet, with or without food or water
- Anytime
*ATTAIN-1 trial: orforglipron at the highest dose alongside a reduced-calorie diet and increased activity, against around 2% on placebo (Wharton S, et al. NEJM 2025;393:1796–1806). Individual results vary.
Dosing
Built up gently, never rushed.
Six strengths, each held for at least 30 days so your body can adjust and side effects stay manageable. Your prescriber sets the pace, and can hold a dose longer whenever that's the right call. Not everyone needs to reach the highest dose.
| Dose | Duration | Stage |
|---|---|---|
| 0.8 mg once daily | Days 1–30 | Starting dose |
| 2.5 mg once daily | Days 31–60 | Work your way up |
| 5.5 mg once daily | Days 61–90 | Work your way up |
| 9 mg once daily | Days 91–120 | Work your way up |
| 14.5 mg once daily | Days 121–150 | Work your way up |
| 17.2 mg once daily | Days 151 onwards | Maximum dose |
Transparent pricing
Once-a-day treatment pricing.
A one-off price, not a subscription. You pay when you order; if a UK-registered clinician decides treatment isn't right for you, you're refunded in full.
Foundayo steps up through six doses, each held for at least 30 days so your body can adjust. Your clinician sets the pace.
| Daily dose | Price |
|---|---|
| 0.8mg | £89 / 30 days |
| 2.5mg | £89 / 30 days |
| 5.5mg | £89 / 30 days |
| 9mg | £109 / 30 days |
| 14.5mg | £139 / 30 days |
| 17.2mg | £139 / 30 days |
Eligibility
Is treatment suitable for you?
Your BMI29.0Overweight
You're likely eligible
Your BMI is in the range where weight-loss treatment is typically considered. A UK-registered clinician confirms suitability in your assessment.
Your BMI is a screening estimate for eligibility, not a diagnosis. Once you have completed your online consultation, a clinician will review your health profile. This will determine whether treatment is right for you.
How it compares
Results or flexibility? Know the trade-off.
The injections and the Wegovy Pill currently edge ahead on trial averages; Foundayo wins on fitting quietly into any routine. No needles, no fridge, no fasting window. Whichever you lean towards, a clinician helps you decide.
| Foundayo | Wegovy Pill | Wegovy | Mounjaro | |
|---|---|---|---|---|
| Active ingredient | Orforglipron | Semaglutide | Semaglutide | Tirzepatide |
| How it's taken | Daily tablet | Daily tablet | Weekly injection | Weekly injection |
| Food & drink rules | None, any time of day | Empty stomach + 30-min wait | None | None |
| Storage | Room temperature | Room temperature | Fridge (2–8°C) | Fridge (2–8°C) |
| Average weight loss* | 11.2% · 72 wks | 16.6% · 64 wks | 20.7% · 72 wks | 21% · 72 wks |
| Availability | Available now | Available now | Available now | Available now |
*Average body-weight change at the highest approved dose in separate clinical trials (ATTAIN-1; OASIS 4; STEP UP; SURMOUNT-1), not head-to-head comparisons. Individual results vary.
Why people choose Curate
Quietly looked after, start to finish.
The team genuinely couldn't be more helpful. Every question answered within hours, no judgement, just proper support whenever I needed it.
Curate patient · 9 months
Ordered in the evening and it arrived two days later in plain packaging. The whole process was quicker and easier than I ever expected.
Curate patient · 4 months
I've felt looked after the whole way through. Friendly clinicians, clear pricing, and a care team that actually checks in on how you're doing.
Curate patient · 6 months
Who it suits
Made for real routines.
- You'd rather take a daily tablet than a weekly injection
- The Wegovy Pill's fasting rules don't fit around your mornings
- Needles are the thing that's been putting you off treatment
- You travel often and want treatment that doesn't need a fridge
- You want to discuss a tablet-based maintenance option after injections
FAQs
Your questions, answered.
The essentials on Foundayo and how ordering works. Anything else, our team is happy to help.
Still have questions? Talk to our team
Is Foundayo available in the UK?
Yes. Foundayo was approved by the MHRA on 10 August 2026, making the UK the first country in Europe to approve it for weight management, and it's available at Curate now. Complete the online consultation and, if a clinician approves your order, your treatment is dispatched in discreet, plain packaging.
How does ordering work?
You complete the online consultation today, which takes about four minutes, then choose your dose and place your order. A UK-registered clinician reviews it, and your treatment is dispatched as soon as your order is approved. If a clinician decides Foundayo isn't right for you, a refund will be set up in line with our terms and conditions.
What is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily GLP-1 tablet made by Eli Lilly, the company behind Mounjaro. Unlike earlier GLP-1 medicines, it's a small-molecule (non-peptide) compound, which is what lets it survive digestion as a tablet and be taken at any time of day, with or without food or water.
How much weight could I lose?
In the ATTAIN-1 trial, adults taking the highest dose lost 11.2% of their body weight on average over 72 weeks, alongside a reduced-calorie diet and increased activity, compared with around 2% on placebo. Just over half lost 10% or more. Individual results vary.
How do I take it?
One tablet a day, swallowed whole, at any time of day, with or without food or water. There's no fasting window and no timing rules, so it fits around your routine rather than the other way round. Don't split, chew or crush the tablet, and keep it in its original packaging at room temperature.
How is it different from the Wegovy Pill?
Both are daily GLP-1 tablets, but they're built differently. The Wegovy Pill is peptide-based, so it must be taken on an empty stomach with a small amount of water and a 30-minute wait before eating. Foundayo's small-molecule structure removes those rules entirely. In separate trials the Wegovy Pill showed a higher average weight loss (16.6% over 64 weeks against 11.2% over 72 weeks), so it's a trade-off between results and flexibility. A clinician can help you weigh it up.
What are the side effects?
Similar to other GLP-1 medicines: mostly digestive (nausea, constipation, diarrhoea, vomiting or indigestion), usually mild to moderate and most noticeable around dose increases. That's why the dose steps up gradually, with each strength held for at least 30 days. If side effects feel serious or aren't settling, your care team is a message away.
Do I need a prescription?
Yes — Foundayo is a prescription-only medicine, so a clinician's review always comes first, which is exactly what the online consultation covers. Be cautious of any website offering to sell Foundayo or orforglipron without one.
Is this a subscription?
No. It's a one-time purchase, not a plan you're locked into, and you're never auto-billed. You pay when you order, and if a clinician decides treatment isn't right for you, a refund will be set up in line with our terms and conditions.
Advice & guides
Weight loss, explained properly.
Weight Loss
Am I eligible for the Wegovy pill? BMI and criteria explained
Eligibility for oral semaglutide rests on BMI, weight-related conditions and your wider health. How the criteria work, and what an assessment actually checks.
Weight Loss
What to eat on the Wegovy pill
The tablet adds a food-timing rule no injection has, and a smaller appetite raises the stakes on what fills it. A practical eating guide for oral semaglutide.
Weight Loss
Can you take the Wegovy pill at night?
Mornings do not suit everyone. Whether night-time dosing of oral semaglutide can work, what the absorption rules demand, and how shift workers can manage.
Available now · from £89
The take-anytime weight loss pill.
A 4-minute consultation, a UK-registered clinician's review, and a full care team behind you. No needles, no fasting window, no subscription.
Start consultation · 4 minYou pay when you order, after your consultation. If treatment isn’t right for you, a refund will be set up in line with our terms and conditions. Orders dispatch in discreet, plain packaging once approved.
References
- Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity (ATTAIN-1). New England Journal of Medicine, 2025;393:1796–1806.
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). The Lancet, 2025.
- Wharton S, et al. Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine, 2025.
- Wharton S, et al. Efficacy and safety of semaglutide 7.2 mg in obesity (STEP UP). Diabetes, 2025.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
- Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK, August 2026.